ReviewTherapeutic advances in gastroenterology2016

Clinical experience with infliximab biosimilar Remsima (CT-P13) in inflammatory bowel disease patients.

Jørgen JahnsenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.